Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Verastem, Inc. (NASDAQ: VSTM).

Full DD Report for VSTM

You must become a subscriber to view this report.


Recent News from (NASDAQ: VSTM)

Verastem Oncology to Present Duvelisib Data at EHA 2018 Annual Meeting
In a phase Ib/II investigational study of duvelisib, a dual inhibitor of PI3K-δ,γ in combination with FCR (dFCR) for frontline therapy of younger CLL patients, dFCR was observed to be a highly active regimen, achieving ORR of 97% and 81% bone marrow MRD negativity Addi...
Source: Business Wire
Date: May, 17 2018 09:50
Verastem Oncology to Present Data on Two Lead Drug Candidates at ASCO 2018 Annual Meeting
Results from the DUO™ crossover study with duvelisib demonstrate superior ORR and PFS compared to prior ofatumumab treatment and consistent with ORR in patients who were initially treated with duvelisib in the DUO™ Study Promising initial clinical activity of defactinib, ...
Source: Business Wire
Date: May, 16 2018 17:09
We Continue To Like Verastem
"Even fools say something worthwhile now and again. Even a blind pig finds an acorn sometimes." - Robert Jordan, The Eye of the World A Tier 4 biotech concern named Verastem ( VSTM ) has been a founding member of the model Busted IPO Forum model portfolio since the fourth quarter of ...
Source: SeekingAlpha
Date: May, 16 2018 12:29
Verastem Oncology Announces Pricing of Public Offering of Common Stock
Verastem, Inc., (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its registered underwritten public offering of 7,777,778 shares of its common stoc...
Source: Business Wire
Date: May, 16 2018 09:29
Premarket Losers as of 9:05 am (5/16/2018)
EOLS   -22%  after FDA rejecting marketing application for prabotulinumtoxinA. More news on: Evolus, Inc., Verastem, Inc., Red Violet, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 16 2018 09:16
After Hours Gainers / Losers (05/15/2018)
Top gainers:   BOOT   +8.4% .  ACRX +3.6% . EBIO   +3.4% . PETQ +3.1% . SUPV   +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 17:35
Verastem Oncology Announces Public Offering of Common Stock
Verastem, Inc. (NASDAQ: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced that it has commenced a registered underwritten public offering of $35 million of its shares of co...
Source: Business Wire
Date: May, 15 2018 16:01
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (Nasdaq: VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock options to ten new employees to purchase an aggregate of 209,000 shares of Verastem Oncology’s common stock...
Source: Business Wire
Date: May, 04 2018 16:05
Verastem Oncology Reports First Quarter 2018 Financial Results
Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the quarter ended March 31, 2018 and provided an overview of certain corporate...
Source: Business Wire
Date: May, 03 2018 16:05
Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day
Duvelisib is Well Positioned to Meet the Evolving Unmet Need in CLL/SLL and FL Company is Laying the Foundation to Optimize the Launch and Commercial Value of Duvelisib Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drug...
Source: Business Wire
Date: May, 03 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-178.378.29498.42278.051,916,024
2018-08-168.108.38018.447.8951,834,879
2018-08-158.048.018.137.821,721,583
2018-08-148.048.008.298.001,249,118
2018-08-138.198.1658.36138.011,875,802

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17253,101533,38447.4519Short
2018-08-16244,428572,52142.6933Short
2018-08-15260,163450,95857.6912Short
2018-08-14137,009379,75136.0786Short
2018-08-13114,955479,83723.9571Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VSTM.


About Verastem, Inc. (NASDAQ: VSTM)

Logo for Verastem, Inc. (NASDAQ: VSTM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: VSTM)

      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: May, 15 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 10 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 13 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Annual statement of changes in beneficial ownership of securities
      Filing Type: 5Filing Source: edgar
      Filing Date: February, 06 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: January, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: December, 21 2017

       

       


      Daily Technical Chart for (NASDAQ: VSTM)

      Daily Technical Chart for (NASDAQ: VSTM)


      Stay tuned for daily updates and more on (NASDAQ: VSTM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: VSTM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VSTM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of VSTM and does not buy, sell, or trade any shares of VSTM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/